Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.
Q2 2024 vs. Q1 2024
How the institutions holding Monte Rosa Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 68 | 1 | 75 | +8 |
| Shares | 39.9M | 15.6K | 45.9M | +6.02M (+15.1%) |
| Value | $281.3M | $110.0K | $171.7M | −$109.5M (−38.9%) |
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Suvretta Capital Management, LLC | 2,659,000 | $9.94M | 0.41% |
| Vestal Point Capital, LP | 890,000 | $3.33M | 0.25% |
| Sphera Funds Management Ltd. | 375,000 | $1.40M | 0.23% |
| Gsa Capital Partners LLP | 25,346 | $95.0K | 0.01% |
| D. E. Shaw & Co., Inc. | 23,422 | $87.6K | 0.00% |
| Squarepoint Ops LLC | 22,665 | $84.8K | 0.00% |
| Castleview Partners, LLC | 18,950 | $70.9K | 0.04% |
| Qube Research & Technologies Ltd | 16,566 | $62.0K | 0.00% |
| Corebridge Financial, Inc. | 16,394 | $61.3K | 0.00% |
| Mirae Asset Global ETFs Holdings Ltd. | 16,270 | $60.9K | 0.00% |
| UBS Asset Management Americas Inc | 15,600 | $58.3K | 0.00% |
| Meeder Asset Management Inc | 10,050 | $37.6K | 0.00% |
| Russell Investments Group, Ltd. | 2,631 | $9.84K | 0.00% |
| The PNC Financial Services Group, Inc. | 28 | $105 | 0.00% |
Sold out (6)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| American International Group, Inc. | 15,246 | $107.5K |
| PDT Partners, LLC | 13,955 | $98.4K |
| Mirae Asset Global Investments Co., Ltd. | 11,946 | $80.9K |
| MetLife Investment Management | 11,419 | $80.5K |
| Metropolitan Life Insurance Co | 1,820 | $12.8K |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 6 | $42 |
Not filed for Q2 2024 yet (1)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Credit Suisse AG | 15,600 | $110.0K |